Literature DB >> 2667863

An immunomodulating drug, thymopentin, in the treatment of progressive systemic sclerosis.

N Giordano, G Biasi, A Taddeo, R Marcolongo, D Bertelletti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2667863     DOI： 10.1007/bf02030091

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  4 in total

1.  Thymopentin: stability considerations and potency by various routes of administration.

Authors:  T K Audhya; G Goldstein
Journal:  Surv Immunol Res       Date:  1985

2.  Abnormalities of immunoregulation in progressive systemic sclerosis. Evidence for excess helper-cell function and altered B-cell function.

Authors:  R S Krakauer; J Sundeen; D N Sauder; A Scherbel
Journal:  Arch Dermatol       Date:  1981-02

3.  A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin.

Authors:  G Goldstein; M P Scheid; E A Boyse; D H Schlesinger; J Van Wauwe
Journal:  Science       Date:  1979-06-22       Impact factor: 47.728

4.  Suppressor cell function and T lymphocyte subpopulations in peripheral blood of patients with progressive systemic sclerosis.

Authors:  T L Whiteside; Y Kumagai; A D Roumm; R Almendinger; G P Rodnan
Journal:  Arthritis Rheum       Date:  1983-07
  4 in total
  1 in total

1.  Preparation and evaluation of poly-butylcyanoacrylate nanoparticles for oral delivery of thymopentin.

Authors:  Weiling He; Xuehua Jiang; Zhi-Rong Zhang
Journal:  J Pharm Sci       Date:  2008-06       Impact factor: 3.534
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.